Shenhua Pharmaceutical

Anhui Shenhua Pharmaceutical is a specialized pharmaceutical manufacturer based in China, primarily focused on the production of active pharmaceutical ingredients (APIs) and finished dosage forms. The company is widely recognized for its expertise in biological polysaccharides, particularly Lentinan, which is utilized as an immunomodulatory adjuvant in cancer therapy. Since its acquisition by Grand Pharmaceutical Group in 2014, Shenhua has integrated into a larger corporate structure, serving as a key production hub for anti-infective and anti-tumor medications. Its facilities are GMP-certified, supporting a diverse portfolio that includes small molecule antivirals and traditional Chinese medicines. The company continues to supply both domestic and international markets with high-quality pharmaceutical products.